 We
are pleased you are visiting our Provectus Pharmaceuticals
Web site. As you will see, our company is engaged in
exciting research & development activities. This
site is intended to provide a useful introduction into
the innovative world of Provectus.
We are a group of dedicated and entrepreneurial
scientists and business people, working together for the past 12 years,
engaged in developing breakthrough technologies for
cancer and other serious diseases. Our primary goal
at Provectus is to develop alternative treatments that
are safer, more effective, less invasive and more economical
than conventional therapies.
Our Provectus Pharmatech division develops ethical
pharmaceuticals for oncology and dermatology. Looking
first to oncology, our novel drugs are designed to selectively
target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing systemic side
effects. In particular, our focus is on melanoma, breast
and liver cancers – among the most difficult
cancers to treat using conventional methods. We are very excited
about the Phase 2 clinical trial of PV-10 that
began in 2007 for melanoma.
Targeting abnormal or diseased cells is also the
approach we use in designing proprietary treatments
for dermatological diseases, in particular, chronic,
severe cases of psoriasis, eczema and acne. We are excited about the
Phase 2 clinical trial of our topical agent PH-10
for psoriasis that began in 2007. In addition, certain
skin cancers may be targeted and treated more safely and
effectively using PH-10.
In addition to our core pharmaceutical work, Provectus
has developed a number of intellectual properties and
technologies in the areas of medical devices and biotechnologies.
Rather than dilute the efforts of Pharmatech, we are
actively pursuing licensure, co-development, spin-offs
and joint ventures of these technologies via our subsidiaries
Provectus Devicetech and Provectus Biotech. Devicetech
encompasses both cosmetic and therapeutic treatments,
with key attention to developing laser-based products
to treat melanoma. Biotech is concentrating on producing
vaccines to prevent certain cancers and other serious
diseases, as well as detecting new viruses that could
be associated with the onset of such diseases.
We added Provectus Imaging and Xantech as subsidiaries with non-core intellectual
property in 2007. Our remaining subsidiary, Pure-ific Corp., is prepped to be
sold or spun off to further develop its over-the-counter products.
We are introducing professional skincare products
for disposable glove users, and novel retail products
for personal hygiene. In addition, we will be introducing
an OTC product for acne sufferers.
We are proud of our intellectual capital at Provectus.
We hold a growing number of U.S. patents in the pharmaceutical, medical
device and biotech fields, with many additional patent
applications in the works in the U.S. and internationally.
Provectus is a significant, emerging player in
the huge and growing pharmaceutical industry. We believe
in our potential to improve health care worldwide, using
breakthrough products that are easy to manufacture and
license, and economical to use. We appreciate your interest
in our company, and welcome your comments and questions.
Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals
|
